Radar›Companies›Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 10
United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 10

A five-company biological products, excluding disgnostic substances cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderDyadic · 57
Strongest available pathPrime Medicine · -80.7%
Widest latest marginCuris · -80.3%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1DYAI · Nasdaq

Dyadic

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1979Jupiter, Florida$24.6M market cap
View full Companies Radar profile
57Moderate
Snapshot price$0.61as of page date
Monthly-close return-89.9%five-year window
FY2025 revenue$0.00BDYADIC INTERNATIONAL INC
Net margin-238.3%FY2025
Prism attention17.1%share across these five
Filing track recordRevenue, USD billions
+28.6%
$0$0.0B$0.0B$0.0BFY2021: $0.002BFY2022: $0.003BFY2023: $0.003BFY2024: $0.003BFY2025: $0.003B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 6.5%
52-week position1% through range
$0.60$1.60
News mentions909
Community mentions0partial coverage
U.S.-scope patents133
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal83/100
Management stability90/100
Market position6/100
Capital-event signal80/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 4 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2PRME · Nasdaq

Prime Medicine

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2019Cambridge, Massachusetts$654.8M market cap
View full Companies Radar profile
46Cautious
Snapshot price$3.61as of page date
Monthly-close return-80.7%since October 2022
FY2025 revenue$0.01BPrime Medicine, Inc.
Net margin-4342.4%FY2025
P/E snapshot-4.1xone ratio, not a verdict
Prism attention5.8%share across these five
Filing track recordRevenue, USD billions
+55.3%
$0$0.0B$0.0B$0.0BFY2024: $0.003BFY2025: $0.005B20242025
FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 55.3%
52-week position22% through range
$2.67$6.94
News mentions307
Community mentions16partial coverage
U.S.-scope patents131
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal69/100
Management stability82/100
Market position3/100
Capital-event signal55/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 1 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3FATE · Nasdaq

Fate Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2007San Diego, California$291.2M market cap
View full Companies Radar profile
39Cautious
Snapshot price$2.43as of page date
Monthly-close return-96.5%five-year window
FY2025 revenue$0.01BFATE THERAPEUTICS INC
Net margin-2051.1%FY2025
P/E snapshot-2.5xone ratio, not a verdict
Prism attention22.7%share across these five
Filing track recordRevenue, USD billions
-88.1%
$0$0.0B$0.1B$0.1BFY2021: $0.056BFY2022: $0.096BFY2023: $0.064BFY2024: $0.014BFY2025: $0.007B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -41.3%
52-week position65% through range
$0.93$3.23
News mentions1.2K
Community mentions85partial coverage
U.S.-scope patents611
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal33/100
Management stability90/100
Market position0/100
Capital-event signal59/100
Innovation pulse10/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 6 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4OCGN · Nasdaq

Histogenics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2013Aurora, Colorado$447.6M market cap
View full Companies Radar profile
38Cautious
Snapshot price$1.32as of page date
Monthly-close return-81.9%five-year window
FY2025 revenue$0.00BOcugen, Inc.
Net margin-1537.4%FY2025
P/E snapshot-4.9xone ratio, not a verdict
Prism attention34.9%share across these five
Filing track recordRevenue, USD billions
-26.9%
$0$0.0B$0.0B$0.0BFY2023: $0.006BFY2024: $0.004BFY2025: $0.004B202320242025
FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -14.5%
52-week position18% through range
$1.00$2.73
News mentions1.9K
Community mentions29partial coverage
U.S.-scope patents120
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal53/100
Management stability90/100
Market position3/100
Capital-event signal25/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5CRIS · Nasdaq

Curis

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2000Lexington, Massachusetts$3.6M market cap
View full Companies Radar profile
27Avoid
Snapshot price$1.49as of page date
Monthly-close return-100.0%five-year window
FY2025 revenue$0.01BCURIS INC
Net margin-80.3%FY2025
P/E snapshot0.4xone ratio, not a verdict
Prism attention19.5%share across these five
Filing track recordRevenue, USD billions
-11.3%
$0$0.0B$0.0B$0.0BFY2021: $0.011BFY2022: $0.010BFY2023: $0.010BFY2024: $0.011BFY2025: $0.009B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -3.0%
52-week position0% through range
$1.40$39.00
News mentions1.0K
Community mentions110partial coverage
U.S.-scope patents1024
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal44/100
Management stability70/100
Market position3/100
Capital-event signal0/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Prime Medicine
-80.7%
Histogenics
-81.9%
Dyadic
-89.9%
Fate Therapeutics
-96.5%
Curis
-100.0%

Latest revenue

USD billions, official filing scope shown on each company card.

Curis
$0.01B
Fate Therapeutics
$0.01B
Prime Medicine
$0.01B
Histogenics
$0.00B
Dyadic
$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Curis
-80.3%
Dyadic
-238.3%
Histogenics
-1537.4%
Fate Therapeutics
-2051.1%
Prime Medicine
-4342.4%

Prism news attention

Normalized share across these five names; attention is not quality.

Histogenics
34.9%
Fate Therapeutics
22.7%
Curis
19.5%
Dyadic
17.1%
Prime Medicine
5.8%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Histogenics leads the conversation

It holds 34.9% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $0.00B.

Price path

Prime Medicine leads the available price paths

Its monthly-close return is -80.7% for the since October 2022. At the other end, Curis is -100.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Curis has the widest latest margin

Its FY2025 net margin is -80.3%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Histogenics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -4.9x while its five-year window price return is -81.9%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · DYAI

Dyadic

909available Prism news records

Prism top themes

Earnings & financial performance
20
Price action & investor response
12
Leadership & governance
8
Capital allocation & transactions
1

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+7.8%110 latest 12m vs 102 prior 12m
2024-01: 9 mentions2024-02: 15 mentions2024-03: 17 mentions2024-04: 4 mentions2024-05: 11 mentions2024-06: 11 mentions2024-07: 11 mentions2024-08: 4 mentions2024-09: 5 mentions2024-10: 5 mentions2024-11: 9 mentions2024-12: 0 mentions2025-01: 6 mentions2025-02: 43 mentions2025-03: 11 mentions2025-04: 3 mentions2025-05: 3 mentions2025-06: 2 mentions2025-07: 7 mentions2025-08: 11 mentions2025-09: 3 mentions2025-10: 16 mentions2025-11: 13 mentions2025-12: 9 mentions2026-01: 8 mentions2026-02: 9 mentions2026-03: 16 mentions2026-04: 8 mentions2026-05: 9 mentions2026-06: 1 mentions2024-012026-06

Machine-classified coverage tone

89.1% positive-2.8 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

vaccine formulation 13diagnostic biotechnology 11subunit vaccines 11viral vector vaccines 10synthetic biology 10enzyme engineering 9mrna vaccines 8fill-finish for vaccines 7

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-12 · trend and themes shown through 2026-06
Areas of research · FATE

Fate Therapeutics

1,208available Prism news records

Prism top themes

Leadership & governance
38
Price action & investor response
22
Legal, arbitration & regulatory
9
Capital allocation & transactions
7
Earnings & financial performance
6

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+20.3%166 latest 12m vs 138 prior 12m
2024-01: 10 mentions2024-02: 12 mentions2024-03: 9 mentions2024-04: 14 mentions2024-05: 22 mentions2024-06: 6 mentions2024-07: 14 mentions2024-08: 12 mentions2024-09: 2 mentions2024-10: 3 mentions2024-11: 20 mentions2024-12: 5 mentions2025-01: 4 mentions2025-02: 23 mentions2025-03: 20 mentions2025-04: 14 mentions2025-05: 15 mentions2025-06: 6 mentions2025-07: 6 mentions2025-08: 10 mentions2025-09: 8 mentions2025-10: 20 mentions2025-11: 7 mentions2025-12: 8 mentions2026-01: 9 mentions2026-02: 12 mentions2026-03: 21 mentions2026-04: 20 mentions2026-05: 37 mentions2026-06: 8 mentions2024-012026-06

Machine-classified coverage tone

94.2% positive+3.0 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

cell-based therapies 61stem cell banking 54cell therapy 41pluripotent stem cells 27stem cell transplantation 22somatic cell therapy 12car-t cell therapy 9gene therapy rare diseases 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-04–2026-06-19 · trend and themes shown through 2026-06
Areas of research · OCGN

Histogenics

1,861available Prism news records

Prism top themes

Legal, arbitration & regulatory
78
Price action & investor response
72
Earnings & financial performance
53
Leadership & governance
37
Capital allocation & transactions
21

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+31.1%333 latest 12m vs 254 prior 12m
2024-01: 8 mentions2024-02: 16 mentions2024-03: 17 mentions2024-04: 77 mentions2024-05: 66 mentions2024-06: 28 mentions2024-07: 10 mentions2024-08: 28 mentions2024-09: 10 mentions2024-10: 20 mentions2024-11: 17 mentions2024-12: 7 mentions2025-01: 10 mentions2025-02: 65 mentions2025-03: 26 mentions2025-04: 17 mentions2025-05: 19 mentions2025-06: 25 mentions2025-07: 15 mentions2025-08: 22 mentions2025-09: 25 mentions2025-10: 16 mentions2025-11: 14 mentions2025-12: 11 mentions2026-01: 37 mentions2026-02: 26 mentions2026-03: 57 mentions2026-04: 59 mentions2026-05: 48 mentions2026-06: 3 mentions2024-012026-06

Machine-classified coverage tone

89.5% positive-1.1 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 152rare disease treatment 44class action securities litigation 30rare disease clinical trials 27cell-based therapies 22stock performance 22stem cell banking 17prospectus liability 14

Keyword tag occurrences in available Prism news records.

Coverage: 2011-07-28–2026-06-03 · trend and themes shown through 2026-06
Areas of research · CRIS

Curis

1,036available Prism news records

Prism top themes

Price action & investor response
19
Earnings & financial performance
13
Legal, arbitration & regulatory
10
Capital allocation & transactions
5
Leadership & governance
5

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-68.2%69 latest 12m vs 217 prior 12m
2023-12: 0 mentions2024-01: 6 mentions2024-02: 3 mentions2024-03: 8 mentions2024-04: 7 mentions2024-05: 11 mentions2024-06: 2 mentions2024-07: 12 mentions2024-08: 5 mentions2024-09: 3 mentions2024-10: 2 mentions2024-11: 3 mentions2024-12: 2 mentions2025-01: 1 mentions2025-02: 154 mentions2025-03: 13 mentions2025-04: 13 mentions2025-05: 7 mentions2025-06: 2 mentions2025-07: 5 mentions2025-08: 6 mentions2025-09: 2 mentions2025-10: 2 mentions2025-11: 4 mentions2025-12: 2 mentions2026-01: 13 mentions2026-02: 2 mentions2026-03: 14 mentions2026-04: 4 mentions2026-05: 13 mentions2023-122026-05

Machine-classified coverage tone

85.7% positive-3.9 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

angiogenesis inhibitors 12stock price 8share price 8stock surge 6stock performance 6cancer biomarkers 5earnings per share 4earnings surprises 4

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-22–2026-05-31 · trend and themes shown through 2026-05
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

FATE

Fate Therapeutics

85 mentions
Stock and valuation
47
Products, pricing and logistics
6
Workplace and hiring
1

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 85 records remained after filtering.

OCGN

Histogenics

29 mentions
Stock and valuation
20

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 29 records remained after filtering.

CRIS

Curis

110 mentions
Stock and valuation
33
Products, pricing and logistics
6
Workplace and hiring
3

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 110 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

DYAI

Dyadic

through 2025-08-05
Earnings releases 5Company announcements 1Listing / IPO 1
  1. Earnings releases

    Dyadic International, Inc. (Nasdaq: DYAI) ... today announced that it will report its financial results for the second quarter 2025.

  2. Listing / IPO

    Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced the pricing of its previously announced underwritten public offering of 6,052,000 shares of common stock at a public offering price of $0.95 per share.

  3. Company announcements

    In March 2024, the company released its financial results for the fiscal year 2023, with the company reporting revenues of $2,899,000

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PRME

Prime Medicine

through 2026-04-27
Earnings releases 2Leadership changes 2Listing / IPO 2
  1. Leadership changes

    Prime Medicine appointed Svetlana Makhni as the biotechnology company’s new chief financial officer.

  2. Earnings releases

    Prime Medicine $2.98 million 235.72 -$195.88 million ($1.56) -3.35

  3. Listing / IPO

    Prime Medicine, the developer of a “search and replace” gene editing platform, has launched an upsized initial public offering (IPO) that raised $175 million in gross proceeds—about $24 million more than projected just last week.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

FATE

Fate Therapeutics

through 2026-05-01
Company announcements 18Lawsuits 11Earnings releases 2Leadership changes 2Listing / IPO 1
  1. Company announcements

    today announced that on May 1, 2026, the Company granted restricted stock units (RSUs) representing 30,200 shares of its common stock to one newly-hired non-executive employee.

  2. Leadership changes

    Fate Therapeutics, Inc. (NASDAQ: FATE) (the Company), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Kamal Adawi, M.S., M.B.A., to the role of Chief Financial Officer (CFO) effective October 20, 2025.

  3. Earnings releases

    now forecasts that the biopharmaceutical company will earn ($1.20) per share for the year

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

OCGN

Histogenics

through 2025-02-14
Listing / IPO 3
  1. Listing / IPO

    pricing an underwritten registered direct offering of about 2.3 million shares (NASDAQ:HSGX) at $2.35 per share.

  2. Listing / IPO

    Histogenics Corp. priced its IPO for expected net proceeds of approximately $57.2 million.

  3. Listing / IPO

    Histogenics Corp. (Waltham, Mass.; HSGX)3 10/7/14 5.9S $11 12.76 Cowen and Co. (co-lead); Needham & Co. (co-lead); Canaccord Genuity (co-lead); BTIG $65

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CRIS

Curis

through 2025-01-24
Earnings releases 2
  1. Earnings releases

    Curis $10.02 million 2.90 -$47.41 million ($7.81) -0.44

  2. Earnings releases

    Reports Q3 revenue $2.8M, consensus $2.54M.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence
2020 extracted base$194.20B–$477.15B
2033 extracted forecast$685.30B–$1.37T
Implied source CAGR8.5%
high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records
Latest 12m volume+9.8%10786 vs 9825 records
Positive classified tone41.7%+4.6 pp vs prior four quarters
2024-01: 892 mentions2024-02: 804 mentions2024-03: 821 mentions2024-04: 790 mentions2024-05: 1,080 mentions2024-06: 758 mentions2024-07: 563 mentions2024-08: 879 mentions2024-09: 628 mentions2024-10: 779 mentions2024-11: 620 mentions2024-12: 655 mentions2025-01: 712 mentions2025-02: 1,067 mentions2025-03: 1,362 mentions2025-04: 999 mentions2025-05: 803 mentions2025-06: 593 mentions2025-07: 966 mentions2025-08: 3,062 mentions2025-09: 751 mentions2025-10: 687 mentions2025-11: 634 mentions2025-12: 660 mentions2026-01: 312 mentions2026-02: 1,077 mentions2026-03: 634 mentions2026-04: 1,323 mentions2026-05: 87 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies
4,078
substance abuse education
3,736
opioid addiction and treatment
3,643
overdose prevention techniques
3,482
controlled substance regulations
3,381
substance abuse overdose fatalities
3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576cannabis policy reform discussions 1,328psychedelic mental health studies 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 46–53. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Scale and margin leadership sit with Curis and Curis

Curis has the largest displayed latest revenue at $0.01B; Curis has the widest displayed latest margin at -80.3%.

Open Curis in Companies Radar
Comparisons
Anomalies

Histogenics has the widest attention-readiness rank gap

It ranks #1 by measured news attention (34.9%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Histogenics in Companies Radar

Prime Medicine shows a price-operating divergence to inspect

Its displayed filing-revenue change is +55.3% while its available monthly-close return is -80.7%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Prime Medicine in Companies Radar
Explanations

Attention measures coverage volume, not quality

Histogenics's 34.9% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Histogenics in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Dyadic's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 57/100 score.

Open Dyadic in Companies Radar

Stress-test the largest divergence before forming a view

Compare Prime Medicine's profile with Prime Medicine's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Prime Medicine in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon